Relmada Therapeutics, Inc. RLMD Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from Relmada Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s current ratio?
- Relmada Therapeutics, Inc. (RLMD) reported current ratio of 18.3× in Q1 2026.
- How has Relmada Therapeutics, Inc.'s current ratio changed year-over-year?
- Relmada Therapeutics, Inc.'s current ratio increased by 245.3% year-over-year, from 5.3× to 18.3×.
- What is the long-term trend for Relmada Therapeutics, Inc.'s current ratio?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s current ratio has grown at a 9.3% compound annual growth rate (CAGR), from 9.4× to 14.6×.
- What does current ratio mean?
- Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.